EUVIMEDEUVIMED entdecken
Crossref

PSMD2 mediates the degradation of CYP1A2 and promotes the progression of metabolic dysfunction-associated steatohepatitis

Min Liu, Tianhao Liu, Dongsheng Liu, Jiaying He, Qin Shao, Jiye Aa, Guangji Wang, Yuan Xie

Drug Metabolism and Disposition · 2026-08 · 54 (8) · 100363

DOI: 10.1016/j.dmd.2026.100363 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2026-08. Verfasst von Min Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China. Hauptthemen laut MEDLINE: Proteasome Endopeptidase Complex, Cytochrome P-450 CYP1A2, Fatty Liver, Metabolic Diseases. Die Arbeit nennt 46 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Sanming Project of Medicine in Shenzhen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite the well recognized downregulation of cytochrome P450 enzymes in metabolic dysfunction-associated steatohepatitis (MASH), the posttranscriptional mechanisms underlying this phenomenon are still not well understood. This study investigates the role of proteasomal degradation in the regulation of CYP1A2, a major hepatic P450 enzyme, during MASH progression. Using a high-fat diet-induced MASH mouse model and palmitic acid-treated hepatocytes model, we found that CYP1A2 protein levels were significantly decreased without corresponding changes in mRNA expression, indicating predominant posttranslational modification regulation. Mechanistically, we first identified 26S proteasome non-ATPase regulatory subunit 2 (PSMD2) as a novel and crucial regulatory factor that dominates the posttranslational degradation of CYP1A2 during MASH development, and confirmed it functions as a key interacting protein mediating the accelerated proteasomal degradation of CYP1A2. Inhibition of proteasome activity with bortezomib or genetic silencing of PSMD2 effectively blocked CYP1A2 degradation and ameliorated hepatocyte lipid accumulation. Importantly, hepatocyte-specific knockdown of PSMD2 in vivo restored CYP1A2 expression and significantly alleviated MASH-associated pathologies, including hepatic steatosis, inflammation, and liver injury. Collectively, these findings establish PSMD2 as a novel and essential modulator that governs the posttranslational degradation of CYP1A2. Moreover, PSMD2 plays a critical role in the progression of MASH, highlighting its potential as a therapeutic target for this disease. SIGNIFICANCE STATEMENT: This study provides the first evidence that hepatocyte proteasome non-ATPase regulatory subunit 2 (PSMD2) drives metabolic dysfunction-associated steatohepatitis pathology by promoting CYP1A2 degradation and lipid accumulation. PSMD2 deficiency alleviates hepatic steatosis, reduces triglyceride and free fatty acid levels, and restores liver function. These findings establish PSMD2 as a critical regulator of lipid metabolism and hepatocyte integrity, positioning it as a promising therapeutic target for metabolic dysfunction-associated steatohepatitis intervention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proteasome Endopeptidase ComplexCytochrome P-450 CYP1A2Fatty LiverMetabolic DiseasesAnimalsMiceHepatocytesMaleMice, Inbred C57BLProteolysisDiet, High-FatDisease ProgressionHumansLiver

Stichwörter der Autor:innen

CYP1A2Metabolic dysfunction-associated steatohepatitisPSMD2Proteasome degradation pathway

Substanzen

Proteasome Endopeptidase ComplexCytochrome P-450 CYP1A2

Autor:innen und Institutionen

  • Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
  • Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China; Research Unit of PK-PD Based Bioactive Components and Pharmacodynamic T…
  • Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China. Electronic address: yuanxie@cpu.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • Sanming Project of Medicine in Shenzhen

Zitieren

APA

Liu, M., Liu, T., Liu, D., He, J., Shao, Q., Aa, J., Wang, G., & Xie, Y. (2026). PSMD2 mediates the degradation of CYP1A2 and promotes the progression of metabolic dysfunction-associated steatohepatitis. Drug Metabolism and Disposition, 54(8), 100363. https://doi.org/10.1016/j.dmd.2026.100363

Vancouver

Liu M, Liu T, Liu D, He J, Shao Q, Aa J, et al. PSMD2 mediates the degradation of CYP1A2 and promotes the progression of metabolic dysfunction-associated steatohepatitis. Drug Metabolism and Disposition. 2026;54(8):100363. doi:10.1016/j.dmd.2026.100363

BibTeX
@article{Liu2026,
  author = {Liu, Min and Liu, Tianhao and Liu, Dongsheng and He, Jiaying and Shao, Qin and Aa, Jiye and Wang, Guangji and Xie, Yuan},
  title = {PSMD2 mediates the degradation of CYP1A2 and promotes the progression of metabolic dysfunction-associated steatohepatitis},
  journal = {Drug Metabolism and Disposition},
  year = {2026},
  volume = {54},
  number = {8},
  pages = {100363},
  doi = {10.1016/j.dmd.2026.100363}
}
Kostenlos starten →